(SREN) Swiss Re - Ratings and Ratios
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0126881561
SREN: Reinsurance, Insurance, Risk Transfer, Property, Casualty, Life, Health
Swiss Re AG is a global leader in wholesale reinsurance and risk management solutions, operating across more than 80 countries. With a rich history dating back to 1863, the company has established itself as a cornerstone of the reinsurance industry, offering a broad spectrum of risk transfer products and services. Its operations are divided into three core segments: Property & Casualty Reinsurance, Life & Health Reinsurance, and Corporate Solutions.
The Property & Casualty Reinsurance segment is the backbone of Swiss Res business, providing coverage for a wide array of risks including natural disasters, engineering failures, aviation accidents, marine losses, and cyber-attacks. This segment is particularly significant for insurers seeking to mitigate large-scale risks and stabilize their balance sheets. Swiss Res expertise in this area makes it a go-to partner for insurers worldwide.
The Life & Health Reinsurance segment focuses on mortality and morbidity risks, offering solutions that help life and health insurers manage their risk exposure. This segment is critical for providing financial security to individuals and families, and Swiss Res long-term perspective and actuarial expertise make it a leader in this field.
The Corporate Solutions segment caters to the risk management needs of mid-sized to large corporations, offering tailored insurance programs that go beyond standard coverage. This includes specialized solutions for emerging risks such as cyber threats and supply chain disruptions, making it an indispensable partner for businesses seeking comprehensive risk protection.
Swiss Res financial health is robust, with a market capitalization of 41,135.87M CHF, reflecting its status as one of the largest reinsurance companies globally. The companys price-to-earnings ratio stands at 13.49, with a forward P/E of 11.15, indicating expectations of stable future earnings. Its price-to-book ratio of 2.03 suggests that the market values its assets at a premium, likely due to its strong brand and historical performance. The price-to-sales ratio of 0.80 highlights its ability to generate significant revenue relative to its market value.
Headquartered in Zurich, Switzerland, Swiss Re benefits from the countrys stable financial environment and stringent
Additional Sources for SREN Stock
SREN Stock Overview
Market Cap in USD | 45,603m |
Sector | Financial Services |
Industry | Insurance - Reinsurance |
GiC Sub-Industry | Reinsurance |
IPO / Inception |
SREN Stock Ratings
Growth 5y | 76.8% |
Fundamental | 0.22% |
Dividend | 52.4% |
Rel. Strength Industry | 9.9 |
Analysts | - |
Fair Price Momentum | 148.76 CHF |
Fair Price DCF | 95.60 CHF |
SREN Dividends
Dividend Yield 12m | 4.36% |
Yield on Cost 5y | 8.39% |
Annual Growth 5y | 1.05% |
Payout Consistency | 87.5% |
SREN Growth Ratios
Growth Correlation 3m | 92.3% |
Growth Correlation 12m | 89.3% |
Growth Correlation 5y | 92.6% |
CAGR 5y | 13.97% |
CAGR/Mean DD 5y | 1.40 |
Sharpe Ratio 12m | 1.82 |
Alpha | 29.39 |
Beta | 0.83 |
Volatility | 17.74% |
Current Volume | 526.3k |
Average Volume 20d | 657.1k |
As of February 19, 2025, the stock is trading at CHF 142.65 with a total of 526,267 shares traded.
Over the past week, the price has changed by +0.67%, over one month by +5.01%, over three months by +14.12% and over the past year by +47.36%.
Neither. Based on ValueRay Fundamental Analyses, Swiss Re is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SREN as of February 2025 is 148.76. This means that SREN is currently overvalued and has a potential downside of 4.28%.
Swiss Re has no consensus analysts rating.
According to ValueRays Forecast Model, SREN Swiss Re will be worth about 175.7 in February 2026. The stock is currently trading at 142.65. This means that the stock has a potential upside of +23.15%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 140.7 | -1.3% |
Analysts Target Price | - | - |
ValueRay Target Price | 175.7 | 23.2% |